← Eichor
Study identifier: NCT06751329 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of DM002 in Patients With Advanced Solid Tumors

Condition: Ovarian Neoplasms · Prostatic Neoplasms · Endometrial Neoplasms  ·  Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

PhasePhase 1/Phase 2
Planned participants280
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of study: The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the we…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (5)

University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma, United StatesRecruiting
The University of Texas, MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Scientia Clinical ResearchRandwick, New South Wales, AustraliaRecruiting
Cancer Care WollongongWollongong, New South Wales, AustraliaRecruiting
Southern Oncology Clinical Research UnitAdelaide, South Australia, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06751329